This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Oxantel is an antihelminthic indicated in the treatment of ascaris, trichocephaliasis, and oxyuriasis infections.
- Generic Name
- Oxantel
- DrugBank Accession Number
- DB13670
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Oxantel (DB13670)
- Weight
- Average: 216.284
Monoisotopic: 216.126263143 - Chemical Formula
- C13H16N2O
- Synonyms
- Oxantel
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Helminthic infection Combination Product in combination with: Pyrantel (DB11156) •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Oxantel pamoate UPY1D732T0 68813-55-8 CCOAINFUFGBHBA-UETGHTDLSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image HELMINTREL Oxantel (5 g) + Pyrantel (5 g) Suspension Oral BIOCHEM FARMACEUTICA DE COLOMBIAS.A. 2006-11-10 2018-06-01 Colombia 
HELMINTREL TABLETAS Oxantel (280.74 mg) + Pyrantel (288 mg) Tablet Oral COASPHARMA S.A.S. 2006-11-10 Not applicable Colombia PAMOATO DE OXANTEL 250 MG/5ML + PAMOATO DE PIRANTEL 250 MG/5 ML SUSPENSIÓN. Oxantel pamoate (5 g) + Pyrantel pamoate (5 g) Suspension Oral COASPHARMA S.A.S. 2008-01-09 Not applicable Colombia PAMOXPEN SUSPENSION ORAL Oxantel pamoate (5 g) + Pyrantel pamoate (5 g) Suspension Oral COASPHARMA S.A.S. 2010-02-03 Not applicable Colombia PIRAXTEL® SUSPENSION Oxantel pamoate (5 g) + Pyrantel pamoate (5 g) Suspension Oral LABORATORIOS COASPHARMA S.A.S - COASPHARMA S.A.S 2007-04-09 Not applicable Colombia
Categories
- ATC Codes
- P02CC02 — Oxantel
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Styrenes
- Direct Parent
- Styrenes
- Alternative Parents
- 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Imidolactams / Hydropyrimidines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Carboxamidines / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds show 1 more
- Substituents
- 1,4,5,6-tetrahydropyrimidine / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Amidine / Aromatic heteromonocyclic compound / Azacycle / Carboximidamide / Carboxylic acid amidine / Hydrocarbon derivative / Hydropyrimidine show 11 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 94AJJ30D9E
- CAS number
- 36531-26-7
- InChI Key
- VRYKTHBAWRESFI-VOTSOKGWSA-N
- InChI
- InChI=1S/C13H16N2O/c1-15-9-3-8-14-13(15)7-6-11-4-2-5-12(16)10-11/h2,4-7,10,16H,3,8-9H2,1H3/b7-6+
- IUPAC Name
- 3-[(E)-2-(1-methyl-1,4,5,6-tetrahydropyrimidin-2-yl)ethenyl]phenol
- SMILES
- CN1CCCN=C1\C=C\C1=CC=CC(O)=C1
References
- General References
- INVIMA Product Information: Vanpar (pirantel pamoate/oxantel pamoate) oral suspension [Link]
- External Links
- ChemSpider
- 4444540
- 1871175
- ChEBI
- 135610
- ChEMBL
- CHEMBL1240977
- ZINC
- ZINC000100025503
- Wikipedia
- Oxantel
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Treatment Hookworm Infections 1 4 Completed Treatment Infection by Trichuris Trichiura 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Suspension Oral 5 g Suspension Oral Tablet, coated Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.659 mg/mL ALOGPS logP 2.26 ALOGPS logP 1.28 Chemaxon logS -2.5 ALOGPS pKa (Strongest Acidic) 9.39 Chemaxon pKa (Strongest Basic) 10.9 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 35.83 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 66.9 m3·mol-1 Chemaxon Polarizability 24.63 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0gbj-4940000000-998846c4eee497430f61 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-0090000000-f26f38db8845d21df33a Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-0090000000-d882ebd06f6a9c8a4659 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-014i-2690000000-6c03037e8426dd9e33e1 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-014j-4930000000-392d8a097ef1c65a4f3e Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0pi1-2900000000-232ec7dcf265be96136b Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-066u-5900000000-3d29021a417b516620da Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 149.5402 predictedDeepCCS 1.0 (2019) [M+H]+ 151.89822 predictedDeepCCS 1.0 (2019) [M+Na]+ 157.9915 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:46 / Updated at May 29, 2021 18:12